Ethypharm completed the acquisition of Altan Pharma from Malin for €105m.

Ethypharm, a European pharmaceutical company, completed the acquisition of Altan Pharma, a specialty pharmaceutical company that develops, manufactures and markets injectable medicines for hospital use, from Malin, a publicly listed company investing in highly innovative life sciences companies, for €105m. "Joining an established European specialty pharmaceutical company, with a strong direct commercial presence in Europe beyond Spain and in major growth territories for injectable medicines, will be a booster for the international expansion of Altan Pharma's product portfolio. Since its inception in 1998, Altan Pharma has been committed to improving patient care by providing specialty medications of superior quality and value for the benefit of patients and caregivers," Guillermo Herrera, Altan Pharma CEO.